Last reviewed · How we verify
NCT05506384
Treatment Study for Problematic Gaming and Gambling
NA trial testing Relaps Preventions Therapy in Pathological Gambling in 160 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 1 May 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Relaps Preventions Therapy
- Treatment as usual
Conditions studied
- Pathological Gambling — all drugs for Pathological Gambling →
- Internet Gaming Disorder — all drugs for Internet Gaming Disorder →
Sponsor
Region Skane — full company profile →
Who can join
Adults 12 to 18, any sex, with Pathological Gambling or Internet Gaming Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is twofold: 1) to evaluate an Relaps Prevention(RP) treatment for Problematic Gaming (PG) and Internet Gaming Disorder (IGD) patients recruited from child and youth psychiatry (CAP) clinics and 2) to test whether the quality of parent-child relationships plays role in the effect of RP treatment and vice versa - whether the RP treatment has a spillover effect on the quality of parent-child relationships.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Relapse prevention therapy for internet gaming disorder in Swedish child and adolescent psychiatric clinics: a randomized controlled trial.
André F, Kapetanovic S, Einarsson I, Trebbin Harvard S, et al · · 2023 · cited 11× · PMID 37928925 · DOI 10.3389/fpsyt.2023.1256413 -
Relapse Prevention Therapy for Problem Gaming or Internet Gaming Disorder in Swedish Child and Youth Psychiatric Clinics: Protocol for a Randomized Controlled Trial.
Kapetanovic S, Gurdal S, Einarsson I, Werner M, et al · · 2023 · cited 9× · PMID 36602846 · DOI 10.2196/44318
Verify or expand the search:
- PubMed search for NCT05506384
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05506384 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05506384.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing